-
Mashup Score: 5FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC - 8 hour(s) ago
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time oncology review, expediting access to this potential treatment.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk #NMIBC https://t.co/Z0U7GPq7WF
-
-
Mashup Score: 0Protara Announces Promising Phase 2 Results for TARA-002 in High-Risk NMIBC | GU Oncology Now - 10 day(s) ago
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
Source: guoncologynow.comCategories: General Medicine News, Oncologists1Tweet-
🧪 Protara Therapeutics has announced encouraging results from the ongoing phase 2 ADVANCED-2 trial, showcasing the potential of its investigational cell-based therapy, TARA-002, in treating HR #NMIBC: https://t.co/NUDYJhbYpo
-
-
Mashup Score: 7Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li - 1 month(s) ago
Zach Klaassen interviews Roger Li about the CORE-001 trial for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Li highlights the significant need for bladder-sparing therapies for patients who are too frail or unwilling to undergo radical cystectomy. The trial explores the combination of cretostimogene grenadenorepvec, an oncolytic immunotherapy, with pembrolizumab. This combination…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Cretostimogene Grenadenorepvec: A novel oncolytic immunotherapy for BCG-unresponsive #NMIBC. @UrogerliMD joins @zklaassen_md to discuss the combination of cretostimogene grenadenorepvec with pembrolizumab in the CORE-100 trial > https://t.co/rZ6XOKB10a https://t.co/2mWy5XOggJ
-
-
Mashup Score: 3PIVOT-006: Phase 3 Trial Comparing Oncolytic Virus Creto vs Observation for Intermediate-Risk NMIBC - Robert Svatek - 1 month(s) ago
Sam Chang hosts Rob Svatek who discusses the PIVOT-006 trial. This phase three trial targets intermediate-risk, non-muscle invasive bladder cancer, comparing a novel therapy, Cretostimogene grenadenorepvec (Creto), against observation. The goal is to enroll 364 patients over 30 months to demonstrate a 10% improvement in recurrence-free survival. The trial focuses on patients who do not qualify…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
PIVOT-006: Phase 3 trial comparing oncolytic virus creto vs observation for intermediate-risk #NMIBC. Robert Svatek @UTHealthSA joins @UroCancerMD to discuss a detailed treatment regimen, aimed at improving patient outcomes with minimal side effects > https://t.co/97EPD6BUer https://t.co/jwy4rshz47
-
-
Mashup Score: 5Cretostimogene Grenadenorepvec: At the CORE and Forming BONDs in High-Risk NMIBC and PIVOTing into Intermediate Risk NMIBC - 1 month(s) ago
PIVOT-006 trial, cretostimogene grenadenorepvec, intermediate risk non-muscle invasive bladder cancer (NMIBC), BCG-failure NMIBC, Cretostimogene grenadenorepvec monotherapy, cretostimogene trials.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Cretostimogene grenadenorepvec: At the CORE and forming BONDs in high-risk #NMIBC and PIVOTing into intermediate-risk NMIBC. @zklaassen_md @GACancerCenter discusses recent advances in this disease space > https://t.co/cO1E8BO0NX @cgoncology @UroOnc https://t.co/LPXCHj9waq
-
-
Mashup Score: 1Navigating NMIBC Risk Stratification and Treatment - Neal Shore - 1 month(s) ago
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Navigating #NMIBC risk stratification and treatment. Neal Shore @CURCMB joins @UroDocAsh @MDAndersonNews to discuss the crucial role of the @AmerUrological guidelines, developed with significant contributions from Dr. Kamat and other leaders in the field > https://t.co/dB8GTF878o https://t.co/ZTPe2rGba6
-
-
Mashup Score: 7Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis - 1 month(s) ago
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Implementing nadofaragene firadenovec treatment in #NMIBC. @MarkTysonMD, Aimee Boden, & Meghann Davis @MayoClinic join @zklaassen_md @GACancerCenter to discuss implementation and logistics and the importance of a comprehensive and collaborative approach > https://t.co/uAvI7jvZrZ https://t.co/XIVCIgK9YE
-
-
Mashup Score: 2Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rates in BCG-Unresponsive NMIBC With CIS - 2 month(s) ago
Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rates in BCG-Unresponsive #NMIBC With CIS https://t.co/vYVfJ2WgNq
-
-
Mashup Score: 2Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rates in BCG-Unresponsive NMIBC With CIS - 2 month(s) ago
Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rates in BCG-Unresponsive #NMIBC With CIS https://t.co/vYVfJ2WgNq
-
FDA Considers TAR-200 in BCG-Unresponsive High-Risk #NMIBC https://t.co/4QgQpfxNI9